vs

Side-by-side financial comparison of Broadridge Financial Solutions (BR) and Moderna (MRNA). Click either name above to swap in a different company.

Broadridge Financial Solutions is the larger business by last-quarter revenue ($1.7B vs $1.0B, roughly 1.7× Moderna). Broadridge Financial Solutions runs the higher net margin — 16.6% vs -19.7%, a 36.3% gap on every dollar of revenue. On growth, Broadridge Financial Solutions posted the faster year-over-year revenue change (-5.4% vs -45.4%). Over the past eight quarters, Broadridge Financial Solutions's revenue compounded faster (10.4% CAGR vs -45.0%).

Broadridge Financial Solutions, Inc. is a public corporate services and financial technology company. Headquartered in Lake Success, New York, the company was founded in 2007 as a spin-off from Automatic Data Processing. Broadridge supplies companies in the financial industry with financial documents such as proxy statements and annual reports, as well as shareholder communications solutions such as virtual annual meetings.

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

BR vs MRNA — Head-to-Head

Bigger by revenue
BR
BR
1.7× larger
BR
$1.7B
$1.0B
MRNA
Growing faster (revenue YoY)
BR
BR
+40.0% gap
BR
-5.4%
-45.4%
MRNA
Higher net margin
BR
BR
36.3% more per $
BR
16.6%
-19.7%
MRNA
Faster 2-yr revenue CAGR
BR
BR
Annualised
BR
10.4%
-45.0%
MRNA

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
BR
BR
MRNA
MRNA
Revenue
$1.7B
$1.0B
Net Profit
$284.6M
$-200.0M
Gross Margin
27.6%
79.6%
Operating Margin
12.0%
-25.6%
Net Margin
16.6%
-19.7%
Revenue YoY
-5.4%
-45.4%
Net Profit YoY
17.1%
-1638.5%
EPS (diluted)
$2.42
$-0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BR
BR
MRNA
MRNA
Q4 25
$1.7B
Q3 25
$1.0B
Q2 25
$2.1B
Q1 25
$1.8B
Q4 24
$1.6B
$966.0M
Q3 24
$1.4B
$1.9B
Q2 24
$1.9B
Q1 24
$1.7B
Net Profit
BR
BR
MRNA
MRNA
Q4 25
$284.6M
Q3 25
$-200.0M
Q2 25
$374.2M
Q1 25
$243.1M
Q4 24
$142.4M
$-1.1B
Q3 24
$79.8M
$13.0M
Q2 24
$323.2M
Q1 24
$213.7M
Gross Margin
BR
BR
MRNA
MRNA
Q4 25
27.6%
Q3 25
79.6%
Q2 25
37.3%
Q1 25
31.8%
Q4 24
27.9%
23.5%
Q3 24
24.5%
72.4%
Q2 24
35.5%
Q1 24
31.2%
Operating Margin
BR
BR
MRNA
MRNA
Q4 25
12.0%
Q3 25
-25.6%
Q2 25
24.1%
Q1 25
19.0%
Q4 24
13.3%
-129.0%
Q3 24
9.4%
-3.8%
Q2 24
22.7%
Q1 24
17.5%
Net Margin
BR
BR
MRNA
MRNA
Q4 25
16.6%
Q3 25
-19.7%
Q2 25
18.1%
Q1 25
13.4%
Q4 24
9.0%
-115.9%
Q3 24
5.6%
0.7%
Q2 24
16.6%
Q1 24
12.4%
EPS (diluted)
BR
BR
MRNA
MRNA
Q4 25
$2.42
Q3 25
$-0.51
Q2 25
$3.17
Q1 25
$2.05
Q4 24
$1.20
$-2.91
Q3 24
$0.68
$0.03
Q2 24
$2.72
Q1 24
$1.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BR
BR
MRNA
MRNA
Cash + ST InvestmentsLiquidity on hand
$371.5M
$1.1B
Total DebtLower is stronger
$3.2B
Stockholders' EquityBook value
$2.9B
$9.3B
Total Assets
$8.6B
$12.1B
Debt / EquityLower = less leverage
1.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BR
BR
MRNA
MRNA
Q4 25
$371.5M
Q3 25
$1.1B
Q2 25
$562.2M
Q1 25
$317.9M
Q4 24
$290.6M
$1.9B
Q3 24
$293.5M
$1.6B
Q2 24
$305.2M
Q1 24
$236.4M
Total Debt
BR
BR
MRNA
MRNA
Q4 25
$3.2B
Q3 25
Q2 25
$3.3B
Q1 25
$3.4B
Q4 24
$3.7B
Q3 24
$3.6B
Q2 24
$3.4B
Q1 24
$3.5B
Stockholders' Equity
BR
BR
MRNA
MRNA
Q4 25
$2.9B
Q3 25
$9.3B
Q2 25
$2.7B
Q1 25
$2.4B
Q4 24
$2.2B
$10.9B
Q3 24
$2.2B
$11.9B
Q2 24
$2.2B
Q1 24
$2.3B
Total Assets
BR
BR
MRNA
MRNA
Q4 25
$8.6B
Q3 25
$12.1B
Q2 25
$8.5B
Q1 25
$8.3B
Q4 24
$8.2B
$14.1B
Q3 24
$8.0B
$15.8B
Q2 24
$8.2B
Q1 24
$8.2B
Debt / Equity
BR
BR
MRNA
MRNA
Q4 25
1.10×
Q3 25
Q2 25
1.22×
Q1 25
1.44×
Q4 24
1.64×
Q3 24
1.63×
Q2 24
1.55×
Q1 24
1.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BR
BR
MRNA
MRNA
Operating Cash FlowLast quarter
$-847.0M
Free Cash FlowOCF − Capex
$-880.0M
FCF MarginFCF / Revenue
-86.6%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BR
BR
MRNA
MRNA
Q4 25
Q3 25
$-847.0M
Q2 25
$699.7M
Q1 25
$360.4M
Q4 24
$236.7M
$825.0M
Q3 24
$-125.5M
$-1.6B
Q2 24
$721.0M
Q1 24
$207.4M
Free Cash Flow
BR
BR
MRNA
MRNA
Q4 25
Q3 25
$-880.0M
Q2 25
$684.1M
Q1 25
$348.9M
Q4 24
$227.9M
$303.0M
Q3 24
$-133.4M
$-1.7B
Q2 24
$703.2M
Q1 24
$184.6M
FCF Margin
BR
BR
MRNA
MRNA
Q4 25
Q3 25
-86.6%
Q2 25
33.1%
Q1 25
19.3%
Q4 24
14.3%
31.4%
Q3 24
-9.4%
-92.2%
Q2 24
36.2%
Q1 24
10.7%
Capex Intensity
BR
BR
MRNA
MRNA
Q4 25
Q3 25
3.2%
Q2 25
0.8%
Q1 25
0.6%
Q4 24
0.6%
54.0%
Q3 24
0.6%
8.1%
Q2 24
0.9%
Q1 24
1.3%
Cash Conversion
BR
BR
MRNA
MRNA
Q4 25
Q3 25
Q2 25
1.87×
Q1 25
1.48×
Q4 24
1.66×
Q3 24
-1.57×
-120.46×
Q2 24
2.23×
Q1 24
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BR
BR

Recurring Fee Revenue Investor Communication Solutions$589.5M34%
Recurring Fee Revenue Capital Markets$300.9M18%
Recurring Fee Revenue Regulatory$248.7M15%
Recurring Fee Revenue Customer Communications$189.2M11%
Recurring Fee Revenue Wealth And Investment Management$179.7M10%
Recurring Fee Revenue Data Driven Fund Solutions$112.7M7%
Event Driven Revenue Mutual Funds$51.4M3%
Event Driven Revenue Equity And Other$39.2M2%
Global Technology And Operations$7.5M0%

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

Related Comparisons